Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Aaron Waxman discusses research into patients with pulmonary hypertension due to interstitial lung disease and the effects of inhaled treprostinil.  Aaron B. Waxman is the director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School.

Image courtesy of Aaron Waxman

Image courtesy of interviewee

Leave a Reply

Your email address will not be published.

×
You may have unlimited institutional access to Faculti. Many colleges and universities have institutional memberships. If you are affiliated with a subscribing institution, please access this site through your SSO/EZproxy/IP address. This should permit you with unlimited views. However, you will not be able to view non-subscribed to content.

If you are not affiliated with a subscribing institution, you can register for free as an individual and view thousands of insights in our archive today or subscribe for subject access.

In addition, all guest visitors to the Faculti website can view any insight monthly. You have insight(s) remaining for this month.
Copyright © Faculti Media Limited 2022. All rights reserved.
error:

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×